Stifel analyst Daniel Arias maintains $Thermo Fisher Scientific (TMO.US)$ with a buy rating, and adjusts the target price from $680 to $665.
According to TipRanks data, the analyst has a success rate of 39.3% and a total average return of -9.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Thermo Fisher Scientific (TMO.US)$'s main analysts recently are as follows:
The company delivered results that matched market anticipations amid heightened expectations. There is recognition of the company's strong execution within a challenging tools demand climate, coupled with a current lack of clarity regarding the timing of demand resurgence.
The company's third-quarter earnings discussion was seen as more optimistic than actual results, and there remains a positive outlook on the stock. This is due to sustained momentum in the Life Sciences Solutions segment and stable sales within the Laboratory Products and Biopharma Services segment, which appears to be resilient to the biotech downturn.
Thermo Fisher is showing a consistent improvement in core growth with quarter-over-quarter increments, and projections suggest a modest rise to approximately +2.5% in the fourth quarter. Expectations for a 5% core growth rate in 2025 appear to be reasonable and justifiable. The company's defensive profile and the potential of its balance sheet continue to be favorable aspects.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析师Daniel Arias维持$赛默飞世尔 (TMO.US)$买入评级，并将目标价从680美元下调至665美元。
根据TipRanks数据显示，该分析师近一年总胜率为39.3%，总平均回报率为-9.8%。
此外，综合报道，$赛默飞世尔 (TMO.US)$近期主要分析师观点如下：
公司发布的结果与市场预期相符，尽管市场对此寄予了更高的期望。在需求环境具有挑战性的工具领域内，公司的强劲执行受到了认可，同时也存在对需求复苏时机的不明朗性。
公司第三季度收益讨论被视为比实际结果更为乐观，对股票仍持有积极预期。这是由于生命科学解决方案部门持续增长势头和实验室产品和生物制药服务部门内稳定销售的持续增长，在生物科技行业下行的背景下似乎仍然受到抵御。
赛默飞世尔展现出核心增长的持续改善，季度增长逐季增加，预测显示第四季度核心增长率将略微增加约2.5%。对于2025年核心增长率达到5%的预期似乎是合理且有理由的。公司的防御性配置和其资产负债表潜力继续是令人满意的方面。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
